View Dr Eric Topol's video summary of what to expect at AHA
NEWS
What's going to be hot at AHA 2009?
Nov 11, 2009 09:00 EDT
Anticipation is building for full trial results from ARBITER 6-HALTS, plus a better understanding of what went wrong with cangrelor in the CHAMPION trials. Also in the lineup are updates from PLATO, RE-LY, ALLHAT, BARI 2D, STICH, CASCADE, POPULAR, HEARTMATE II, and many more. Indeed, this year's "late-breaking" sessions include more than 30 trials over five days.

Late-Breaking Clinical Trials

Late-Breaking Clinical Science

News
What's going to be hot at AHA 2009?
2 COMMENTS - Nov 11, 2009 09:00 EST
Anticipation is building for full trial results from ARBITER 6-HALTS, plus a better understanding of what went wrong with cangrelor in the CHAMPION trials. Also in the lineup are updates from PLATO, RE-LY, ALLHAT, BARI 2D, STICH, CASCADE, POPULAR, HEARTMATE II, and many more. Indeed, this year's "late-breaking" sessions include more than 30 trials over five days.
Murmurs
Interventional cardiologist Donald Baim dies
16 COMMENTS - Nov 6, 2009 18:22 EST
UPDATED // Interventional cardiologist Dr Donald Baim, chief medical and scientific officer at Boston Scientific, has died.
Lipid/Metabolic
Not all metabolic syndrome is created equal: Framingham Offspring analysis
1 COMMENT - Nov 5, 2009 11:45 EST
The syndrome (defined by ATP III criteria) can predict increased cardiovascular and mortality risk or not, depending on which three of five risk factors contributed to the diagnosis, a cohort study suggests; its investigators caution that their observations are only preliminary.
heartbriefs
heartbriefs
View all »
Editorial series
A series of discussions among editorial leaders, developed by theheart.org

Editorial series
Life and times of leading cardiologists with Rob Califf. Guest: Bob Harrington
2 COMMENTS - Nov 6, 2009 09:50 EST
Raised in a blue-collar neighborhood of Somerville, MA, Dr Bob Harrington was blessed to have a strong family and the Jesuits on his side as he traveled from "Yankee" Boston to Duke University. Join him as he tells his story to Dr Rob Califf.
Editorial series
New directions for management of patients with atrial fibrillation
Nov 11, 2009 09:50 EST
New agents and interventions are paving the way for revised modalities in the management of patients with atrial fibrillation. Join Drs Alpert and Delascio Lopes for a review of the latest findings and options.
Editorial series
Clinical research: Comparing regulatory pathways in US and UK
Oct 30, 2009 12:35 EDT
How do regulatory pathways differ in the US and UK? Drs Harrington, Bhatt, and Cleland share their experiences and offer insight on how to support innovative research.
Editorial series
Afib treatment: The five-year plan
Oct 23, 2009 10:40 EDT
Dr Melissa Walton-Shirley talks to Dr Nassir Marrouche about the results of RE-LY, the impact of dronedarone on the treatment of atrial fibrillation, and his hopes for the future of MRI-guided ablation.
Discussion and opinions
Lively, interactive exchanges moderated by thought leaders, staff or contributors to theheart.org

Topolog
Dabigatran: Crossing a remarkable threshold
Wed Oct 14 11:00:00 EDT 2009
The exciting results of the RE-LY trial appear to mark the beginning of a new era in anticoagulation for atrial fibrillation. Will dabigatran be the drug to replace warfarin, at last? How do you think these findings will improve patient care?
theheart.org Forum
Discussions among healthcare providers, clinicians, and researchers.
Visit the forum »
Arrhythmia/EP
Natural ventricular rate a powerful risk predictor in ICD trial
Nov 12, 2009 17:15 EST
It's routinely assessed but underappreciated as a risk marker: the natural, unpaced heart rate of patients with implanted defibrillators was a strong, independent predictor of poor clinical outcomes in a retrospective analysis.
Murmurs
William Ganz, innovative cardiologist, scientist, and inventor, dies
Nov 12, 2009 15:15 EST
Pioneering interventional cardiologist William Ganz dies.
Medscape Medical News
SGR repair bill failure could cool physician support for healthcare reform
Nov 12, 2009 15:00 EST
Now that the US House of Representatives has passed a healthcare reform bill, organized medicine anticipates another vote—possibly next week—on a second bill that would rewrite Medicare's controversial sustainable-growth-rate formula for physician reimbursement.
Interventional/Surgery
DES fractures occur more often than thought
2 COMMENTS - Nov 12, 2009 13:15 EST
A new postmortem study using high-resolution imaging has found that fractures in drug-eluting stents may be more common than thought. However, the majority of such fractures appear to be low-grade and silent, with likely few clinical implications, say the researchers.
Lipid/Metabolic
Total- and HDL-cholesterol levels, not triglycerides, predict vascular risk
Nov 12, 2009 10:00 EST
Clinicians can simplify their existing risk-assessment tools by measuring either total- and HDL-cholesterol levels or apolipoproteins, and this assessment can effectively be done in patients who did not fast before the test.
Interventional/Surgery
ASTRAL finds no benefit of revascularization over medical therapy alone for renal-artery stenosis
3 COMMENTS - Nov 11, 2009 17:00 EST
Percutaneous revascularization of atherosclerotic renal arteries improves patency, but its benefits on renal function have been evaluated only in small studies. The 806-patient ASTRAL trial found no evidence of benefit from revascularization.
Interventional/Surgery
Regions with high rates of carotid-stenting adoption have poorer outcomes
Nov 11, 2009 11:15 EST
Results from a new study suggest that, as the use of carotid artery stenting has become more widespread following expanded Medicare coverage, overall revascularization outcomes have worsened.
Clinical cardiology
Walking speed predicts CV mortality in older people
2 COMMENTS - Nov 10, 2009 19:01 EST
Fast walkers should find themselves less likely to succumb to cardiovascular death, according to a new French study in older adults. Measuring general fitness in this way could easily be incorporated into a general global assessment of cardiovascular risk, say the researchers.
Prevention
No benefits of aspirin for primary prevention in diabetics, meta-analysis suggests
6 COMMENTS - Nov 10, 2009 17:15 EST
Most guideline documents recommend aspirin for primary prevention in people with diabetes, but a new meta-analysis has found no benefit of the widely used drug across a range of different cardiovascular end points. The results speak to the need for dedicated randomized trials, investigators say.
Acute Coronary Syndromes
Clopidogrel effects in men vs women
Nov 10, 2009 16:15 EST
A new meta-analysis has suggested that clopidogrel reduces cardiovascular events and increases bleeding in both men and women, without significant differences between the sexes.
Educational partnerships


  • What Happened at CCC 2009?

    A University of Alberta Perspective
    Drs. Armstrong, Ezekowitz, and Welsh as they discuss the latest data to come out of the 2009 sessions of the Canadian Cardiovascular Congress, from Edmonton, Alberta.


  • What Happened at ESC 2009?

    DUKE Heart Center and DUKE Clinical Research Institute
    Drs. Rao, Alexander, Newby, and O'Connor discuss RE-LY, PLATO, and MADIT-CRT.


  • What Happened at ESC 2009?

    Mayo Clinic
    Drs. Gibbons and Jaffe discuss Antiplatelet therapy in ACS, Atrial Fibrillation, Higher dose clopidogrel and aspirin and CRT therapy in patients with Class I or II heart failure.


  • What Happened at HFSA 2009?

    Cleveland Clinic
    Drs. Young, Starling, and Mountis discuss the latest on cardiac resynchronization, ICDs, exercise and heart failure, women in clinical trials, and guidelines.

Most popular
  1. Interventional cardiologist sues hospital under Whistleblower's Act
  2. Latest European and US STEMI guidelines compared and contrasted
  3. Interventional cardiologist Donald Baim dies
  4. No benefits of aspirin for primary prevention in diabetics, meta-analysis suggests
  5. Off-pump CABG shows no benefit over on-pump approach: ROOBY study
  6. Imaging study shows plaque regression with niacin vs placebo
  7. Low-cholesterol/cancer studies should "dispel lingering doubts" of causal link
  8. Walking speed predicts CV mortality in older people
  9. CMS set to cut Medicare physician fees for cardiovascular imaging
  10. Enrollment halts in randomized trial of CPR for out-of-hospital arrest
View all news »
  1. Interventional cardiologist Donald Baim dies
  2. CMS set to cut Medicare physician fees for cardiovascular imaging
  3. Imaging study shows plaque regression with niacin vs placebo
  4. No benefits of aspirin for primary prevention in diabetics, meta-analysis suggests
  5. Off-pump CABG shows no benefit over on-pump approach: ROOBY study
  6. Latest European and US STEMI guidelines compared and contrasted
  7. A fish tale with merit: Omega-3 PUFAs underrated for heart failure
  8. Interventional cardiologist sues hospital under Whistleblower's Act
  9. Blood products should be used conservatively in heart-surgery patients, trial shows
  10. ASTRAL finds no benefit of revascularization over medical therapy alone for renal-artery stenosis
View all discussions »
button

The Heart of a Woman
Drs. Hayes and Foody and a committee of experts address the gaps and correct the misconception that CVD is more common in men than women.
View all programs »
View all »
Info from Industry
Also on theheart.org
Editorial series
Life and times of leading cardiologists with Rob Califf. Guest: Peter Sleight
2 COMMENTS - Oct 13, 2009 10:15 EDT
With the ISIS-1 trial, Dr Peter Sleight and his team at Oxford changed the approach to cardiovascular research. Join Dr Robert Califf as he talks to Dr Sleight about his journey from London to San Francisco to Oxford and finally to Italy, where he discovered the music of the heart.
The Cardiology Show
Best of Barcelona: PLATO and RE-LY
Sep 2, 2009 11:15 EDT
Dr Valentin Fuster returns to the city where he was born for a scintillating discussion with Drs Fox, Gershlick, Marrouche, Messerli, Spaulding, Vergheugt, Virmani, and Yancy about the miracle of RE-LY and the striking success of ticagrelor in the PLATO study.